Phase 3 Mesothelioma Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have signed a consent form agreeing to take part in the study
• People aged 18 or older at the time of signing the consent form
• People who have been diagnosed with malignant pleural mesothelioma (a type of cancer affecting the lining of the lungs), confirmed through laboratory testing of tissue
• People who have had a specific type of surgery called pleurectomy/decortication (P/D) with no visible cancer left behind after the operation (a simpler surgery called total pleurectomy is allowed for early-stage cases without certain involvement of lung tissue)
• People who have no detectable signs of remaining cancer on a CT scan taken after surgery
• People who have received at least 4 cycles of a chemotherapy combination (platinum plus pemetrexed) before or after surgery, or both — fewer than 4 cycles may be considered in some cases based on medical decisions (confirm with trial site)
• People who joined the study within 50 days of surgery (if chemotherapy was given before surgery), or within approximately 30 days of the last chemotherapy dose (if chemotherapy was given after surgery)
• People who have a general health and activity level rated 0 or 1 on a standard medical scale, meaning they are fully active or have only minor limitations in physical activity
• People who can provide a stored tumour tissue sample (either a block of preserved tissue or at least 10 prepared slides) along with a pathology report, for research purposes
• People whose recent blood test results (taken within 14 days before starting the study treatment) show that their blood cell counts, liver function, kidney function, and other organ markers are within acceptable ranges as defined by the trial
• Women who could become pregnant and who agree to use a highly effective form of contraception (with less than 1% failure rate per year) or remain abstinent during treatment and for 5 months after the last dose of study medication, and who agree not to donate eggs during that period
• Women of childbearing potential must have a negative blood pregnancy test within 14 days before starting study treatment

Who may not be able to join:

• People who still have visible cancer remaining after surgery, as shown on a CT scan after surgery or after chemotherapy
• People with an active autoimmune disease (a condition where the immune system attacks the body) — though some milder conditions such as vitiligo, type 1 diabetes, thyroid conditions managed with hormone replacement, or psoriasis not needing systemic treatment may still be eligible (confirm with trial site)
• People who have had another cancer in the past 5 years, with the exception of certain skin cancers or early-stage cervical cancer that has been treated with the intent to cure
• People with an active infection that requires treatment through the bloodstream or whole body
• People who test positive for HIV
• People with active Hepatitis B or Hepatitis C infection
• People with a history of certain lung conditions, including idiopathic pulmonary fibrosis, organising pneumonia, drug-induced lung inflammation, or unexplained lung inflammation — or those who show signs of active lung inflammation on a CT scan at the start of the study
• People with known active tuberculosis
• People who have had a significant heart or blood vessel event (such as a heart attack or stroke) within the 3 months before starting the study, or who have an unstable heart rhythm or unstable chest pain
• People who have had a major surgical procedure (other than for diagnosis) within 4 weeks before starting the study, or who are expected to need major surgery during the study
• People who have had a serious infection within 4 weeks before starting the study, including infections requiring hospitalisation, blood infections, or severe pneumonia
• People who have previously received a bone marrow or solid organ transplant from another person
• People with any other serious illness, physical finding, or lab result that could make study treatment unsafe or affect the reliability of study results
• People who have received a live or weakened (attenuated) vaccine within 4 weeks before starting the study, or who are expected to need one during treatment or within 5 months of the last dose
• People currently receiving antiviral treatment for Hepatitis B
• People who have received another experimental treatment within 28 days before starting the study
• People who have previously been treated with certain types of immune-based cancer therapies, including anti-CTLA-4, anti-PD-1, or anti-PD-L1 antibodies, or CD137-stimulating treatments
• People who have received immune-stimulating treatments (such as interferon or interleukin-2) within 4 weeks or 5 drug half-lives (whichever is longer) before starting the study
• People who have taken immune-suppressing medications (such as corticosteroids, methotrexate, or similar drugs) within 2 weeks before starting the study, or who are expected to need them during the study — though some exceptions may apply for short-term or low-dose use (confirm with trial site)
• People who have had a severe allergic reaction to certain types of antibody-based medicines
• People with a known allergy to any ingredient in the study drug (atezolizumab), including products derived from Chinese hamster ovary cells
• People who are pregnant, breastfeeding, or planning to become pregnant during the study or within 5 months of the last dose of study treatment

Important: Always verify eligibility with the trial site directly before applying.